Lilly Oncology Medical (@LillyOncMed) “🔬 FRAmework 01 | Now Enrolling A phase 3 trial evaluating a FRα targeting ADC i” — TopicDigg
Lilly Oncology Medical
@LillyOncMed
Dedicated to communicating the latest science & disease state education from Lilly Oncology. Intended for U.S. HCPs. Community Guidelines:
加入 March 2022
597 正在关注 6.6K 粉丝
🔬 FRAmework 01 | Now Enrolling
A phase 3 trial evaluating a FRα targeting ADC in patients with ovarian cancer.
Key details:
- PSOC and PROC
- All FRα expression levels
- Prior mirvetuximab permitted
Click below to learn more about trial details and enrollment
显示更多
